Editas Medicine (NASDAQ:EDIT) reported Q4 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $3.66 million.
Editas Medicine (NASDAQ:EDIT) reported Q4 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $3.66 million.